Except where otherwise noted, all currency amounts are stated in United States dollars. Financial and Operational Highlights Production in the fourth quarter was 2,364,000 tonnes of methanol compared to 2,212,000 tonnes in the third quarter of 2025. Continued to progress the acquisition integration plan with a focus on safe and reliable operations, ending 2025 with the best two-year safety record in Methanex history. Achieved an average realized price in the fourth quarter of $331 per tonne compared to $345 per tonne in the third quarter of 2025. For the fourth quarter of 2025, Adjusted EBITDA was $186 million, Adjusted net loss was $11 million, and net loss attributable to Methanex shareholders was $89 million. The net loss was largely driven by the non-cash impairment expense of $82 million (inclusive of tax) recorded relating to our New Zealand operations. Full year 2025 net income attributable to Methanex shareholders of $80 million, Adjusted EBITDA of $808 million and cash flows from operating activities of $1,016 million. In 2025, $54 million was returned to shareholders through regular dividends and $200 million of the Term Loan A was repaid with cash flows generated from operations, in line with our goal to deleverage the balance sheet. We ended the year with $425 million in cash. VANCOUVER, BRITISH COLUMBIA, March 05, 2026 (GLOBE NEWSWIRE) -- For the fourth quarter of 2025, Methanex (TSX:MX) (Nasdaq:MEOH) reported a net loss attributable to Methanex shareholders of $89 million ($1.15 net loss per common share on a diluted basis) compared to a net loss of $7 million ($0.09 net loss per common share on a diluted basis) in the third quarter of 2025. Adjusted EBITDA for the fourth quarter of 2025 was $186 million and Adjusted net loss was $11 million ($0.14 Adjusted net loss per common share). This compares with Adjusted EBITDA of $191 million and Adjusted net income of $5 million ($0.06 Adjusted net income per common share) for the third quarter of 2025. Rich ...

100% Of Audited Medicaid Claims For Autism Care In Colorado Were Improper Or Flawed: Report Authored by Sylvia Xu via The Epoch Times (emphasis ours), Colorado’s Medicaid program made an estimated $77.8 million in improper payments and another $207.4 million in potentially improper payments for autism therapy, according to a February report from the Inspector General for the Department of Health and Human Services. A sign in front of the Centers for Medicare and Medicaid Services building in Woodlawn, Md., on March 19, 2025. Kayla Bartkowski/Getty Images Auditors investigated $289.5 million in Medicaid payments from 2022 to 2023 that paid for more than 1 million claims for Applied Behavior Analysis—a therapy used to treat autism and developmental disabilities. Each of the 100 claims reviewed contained at least one improper or potentially improper payment, suggesting a 100 percent failure rate. Improper payments are not necessarily fraudulent. Payments are considered improper when the claim does not meet federal or state requirements. Payments are potentially improper when the submitted claim is so poor or unreliable that auditors cannot verify that the services were provided correctly. Claim Errors In 93 of 100 claims examined, the billing providers either did not provide notes verifying that the therapy took place, didn’t provide the required signatures, or billed for more time than the notes indicated. In 18 cases, the therapy that was supposed to be performed by a specialist—such as a Board Certified Behavior Analyst—was performed by staff without those qualifications. In seven cases, the children receiving therapy lacked a current doctor’s diagnosis or referral on file. In 88 cases, facilities billed for recreational activities that are not considered medical therapy, such as academic tutoring, day care, or custodial care. In one case, a facility billed for children swimming and playing on water slides. In 76 cases, facilities billed for a full eight-hour day wi...

Yuan financing has never been as popular as it is now, with more countries and foreign companies tapping the market, in a sign that China’s ambition to internationalize its currency is bearing fruit. Bonds, either sold within China by overseas entities or issued elsewhere, raised a record 218 billion yuan ($31.6 billion) already this year, as the Indonesian government and Wall Street’s Morgan Stanley joined the binge. That adds to the equivalent of $167 billion borrowed via notes and loans in 2025, a tripling in just five years. The yuan’s growing importance as a global funding currency reinforces China’s push for greater influence in finance and trade, just as the US upsets allies and markets alike with its America First policy. The drive is supported by a renminbi bouncing back from a 17-year low and cheap borrowing costs, and more importantly takes advantage of a desire by some investors to diversify away from the dollar. There are signs Beijing wants more, with the People’s Bank of China last month ramping up support for cross-border financing, while prominent Chinese economists argue for looser capital controls given the historic opportunity to boost the yuan’s global appeal. Since late last year, Wall Street analysts have been flocking to forecast further strength for the currency. “The yuan’s internationalization is gaining real traction, especially in trade settlement and financing,” said Aidan Yao , senior investment strategist for Asia at Amundi Investment Institute. “With a growing share of settlements in yuan for Chinese imports, countries need to hold more yuan, driving demand that spills over into the offshore bond market and creates a virtuous cycle.” A key driver of demand for yuan financing is the lower interest rates in China, where deflationary pressures have persisted. When Indonesia issued a dual-currency bond last month, it sold its 10‑year offshore yuan note at about one percentage point below what it paid on a euro tranche that matures in eig...

Asics Corp. is accelerating its global expansion by taking greater control of marathon infrastructure, a strategy executives say will deepen engagement with runners and convert that access into faster growth in running-shoe sales. The 77-year-old Japanese sportswear maker has been acquiring race-registration platforms in markets including Thailand, Spain, France and Australia. These platforms are being linked with Asics’ membership program to create an ecosystem: runners can register for races, use the company’s tracking app, and receive personalized training plans and footwear recommendations months before race day. Asics views the Sydney Marathon as a successful model, which it would like to roll out as a “best practice,” Chief Operating Officer Mitsuyuki Tominaga said. “Not only do we want to sponsor major marathon events, we want to engage with them directly.” Such early access offers a structural advantage as the industry shifts toward direct-to-consumer models. Few global rivals have bought race-registration platforms at scale and rely instead on high-profile athlete ambassadors — giving Asics a relatively uncontested channel to reach runners. It’s another creative bet for Chief Executive Officer Yasuhito Hirota , under whom Asics has pulled off one of corporate Japan’s most notable turnarounds. The company’s operating profit has climbed sixfold in four years to ¥142 billion ($903 million), reversing a ¥4 billion loss in 2020, while its valuation has surged to about ¥3.4 trillion. Asics says the new strategy is already paying off: sales at its booth during the Sydney Marathon in August rose fourfold from the previous year, while e-commerce sales increased 8.3% to ¥148.4 billion. The strategy was on display at the Tokyo Marathon this month. Revenue at the race expo rose by double digits compared with the previous year, according to the company. Monique Johnson, visiting from Houston for her first Tokyo Marathon, said she typically wears other brands but purchas...

Peter Cade/DigitalVision via Getty Images I was a former shareholder of travel software company Sabre Corporation (NASDAQ: SABR ). I purchased shares and call options early on during the pandemic when travel-related stocks plunged in the wake of the global travel shutdown. While SABR stock initially tried to bounce back, the company never really recovered operationally. I eventually exited my position at a loss. I downgraded shares initially to a hold rating and then subsequently to a sell rating last summer following its Q2 results as the company's downward trajectory continued. That bearishness seemed justified heading into 2026. SABR stock proceeded to new all-time lows in February. However, the stock has now doubled off the lows in just a matter of days, including a 36% jump on Monday: Data by YCharts The stock rallied on news that Canadian software conglomerate Constellation Software ( CSU:CA , CNSWF ) has taken a 9.7% stake in Sabre. So, is it time to follow the smart money and take a stake in SABR stock? I'm not doing so personally. Here's why I remain skeptical about Sabre's outlook. Constellation Takes A Stake This past weekend, Sabre disclosed that Constellation had acquired a 9.7% economic interest in Sabre. It bought this position between April and November of 2025, suggesting that Constellation likely has a cost basis of somewhere between $2 and $3 per Sabre share. Constellation bought a 4.7% position in SABR stock outright, along with an additional 5% holding via derivative instruments. For those unfamiliar, Constellation is a serial software acquirer that buys dozens of different, typically small- and mid-sized software companies every year. In the past, one of Constellation's subsidiary operating groups, Vela Software, has been active in the travel software space. So, Sabre could be seen as a natural (if far larger) acquisition in line with these prior moves into the travel segment. According to Sabre's press release, Constellation had requested two ...

The US Securities and Exchange Commission will end its lawsuit against crypto billionaire Justin Sun . The SEC sued Sun in 2023 , alleging he committed securities fraud and bilked investors by working with companies he owned and controled - the Tron Foundation , BitTorrent Foundation Ltd., and Rainberry Inc. — to sell unregistered securities. Sun didn’t immediately return a request for comment.

U.S. Speaker of the House Mike Johnson (R-LA) speaks with the media on the day of classified briefings for the U.S. Senate and House of Representatives on the situation in Iran, on Capitol Hill in Washington, D.C., U.S., March 3, 2026. Kylie Cooper | Reuters The House of Representatives on Thursday rejected a war powers resolution to restrict President Donald Trump 's authority to use the U.S. military in Iran. The vote was 212-219, with four Democrats joining Republicans to torpedo the measure and two Republicans joining Democrats in voting for the measure. The Senate shot down a similar measure on Wednesday. Read more CNBC politics coverage Iran foreign minister: Not seeking ceasefire, warns U.S. invasion would be ‘big disaster for them’ Epstein files: DOJ plans to release new batch of documents ‘fairly soon,’ MS NOW reports Sen. Merkley proposes prediction market ban for government officials after Maduro, Iran bets The votes, while largely symbolic, show Congress is not currently willing to rein in Trump on Iran. Trump began a bombardment of Iran on Saturday, which killed the country's leader, Ayatollah Ali Khamenei. He and his administration have stated myriad aims for the conflict. Democrats and some Republicans have argued that Trump needs the approval of Congress to conduct the operation. The Constitution vests the authority to declare war in Congress. If it passed, the measure would have been largely symbolic. Trump is almost certain to veto any bill that would reduce his authority to use the military.

Immatics press release ( IMTX ): FY GAAP EPS of - € 1.61. Revenue of € 48.2M. More on Immatics Immatics: PRAME Leader's Transition To Commercial Reality Seeking Alpha’s Quant Rating on Immatics Historical earnings data for Immatics Financial information for Immatics

CHUNYIP WONG/E+ via Getty Images Japanese stocks have finally taken a breather. The WisdomTree Japan Hedged Equity Fund ETF ( DXJ ) has dropped almost 8% from its late-February all-time high. That came after a torrid 95% rally off its April 2025 low. I had a "B uy" rating on DXJ back in August last year , and shares have returned 26% since then, the latest decline notwithstanding. Today, while there may be some technical downside risk into the springtime, I still generally like macro trends in the land of the rising sun. Japan’s P/E ratio has ticked up, so it's no longer a bargain, but given fiscal changes and evolving corporate trends within the island nation (such as an increased focus on shareholders), I believe the long-term growth story is still intact. DXJ Has Outperformed, But Has Turned Lower In March StockCharts.com Japan's P/E Ventures Higher JPMAM Japan: Significant Multiple Expansion YoY Goldman Sachs According to the issuer , DXJ seeks to provide exposure to the Japanese equity market while hedging exposure to fluctuations between the U.S. dollar and the yen. The ETF is used by investors to gain broad equity exposure to Japanese dividend-paying companies with an exporter tilt. Currency hedging techniques are employed to mitigate risks around volatility with the Japanese yen. DXJ is a medium-sized ETF, now with $6.2 billion in assets under management, as of March 4, 2026. That’s almost double the AUM from back at the time of my previous analysis. The annual expense ratio is moderate at 48 basis points, while the trailing 12-month dividend yield is low at 1.15% (about on par with that of the S&P 500). Share-price momentum is rated very strong by Seeking Alpha’s quantitative scoring system at an A+. Of course, the very recent dip will have a negative impact on that grade soon, I believe. Still, the yen-hedged, export-focused Japanese ETF sports solid risk characteristics , despite the tick up in both realized and implied volatility. The current implied vol...

US equity indexes fell while government bond yields jumped on Thursday as the Middle East war escala Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles.

Ophir Asset Management initiated a new position in Magnite (MGNI +2.39%) during the fourth quarter, purchasing 2,384,187 shares worth $38.70 million, according to a February 17, 2026, SEC filing. What happened According to an SEC filing dated February 17, 2026, Ophir Asset Management reported acquiring 2,384,187 shares of Magnite during the fourth quarter. The firm had no prior position in Magnite; the quarter-end value of the new stake stood at $38.70 million, reflecting both the purchase and stock price changes within the period. What else to know This was a new position; Magnite now accounts for 4.34% of Ophir Asset Management Pty Ltd’s reported U.S. equity assets. Top holdings after the filing: NYSE: VVX: $49.76 million (5.6% of AUM) NYSE: AIR: $45.49 million (5.1% of AUM) NASDAQ: SIMO: $43.34 million (4.9% of AUM) NASDAQ: HURN: $42.24 million (4.7% of AUM) NASDAQ: MRX: $41.70 million (4.7% of AUM) As of Thursday, shares of Magnite were priced at $14.16, down about 2% for the year and well underperforming the S&P 500’s roughly 16% gain in the same period. Company overview Metric Value Price (as of Thursday) $14.16 Market capitalization $2 billion Revenue (TTM) $702.57 million Net income (TTM) $57.97 million Company snapshot Magnite provides a sell-side advertising platform enabling publishers to manage and monetize digital advertising inventory across CTV channels, applications, websites, and digital media properties. The company operates a technology-driven business model generating revenue primarily from fees charged to publishers and buyers for facilitating digital ad transactions. It serves digital publishers, CTV operators, advertisers, agencies, and demand-side platforms in the United States and internationally. Magnite, Inc. operates an independent sell-side advertising platform with international operations and a focus on connected TV and digital media. The company leverages proprietary technology to optimize ad inventory monetization for publishers and ...

(RTTNews) - Quanex Building Products Corp. (NX) on Thursday, reported financial results for the first quarter ended January 31, 2026. The company's net sales increased to $409.09 million from $400.04 million in the same quarter last year. Quanex Building Products reported a net loss of $4.07 million, or $0.09 per share, compared to a net loss of $14.89 million, or $0.32 per share, in the prior-year quarter. Operating income was $2.85 million, compared to an operating loss of $6.98 million a year earlier. Quanex paid a quarterly dividend of $0.08 per share. NX is currently trading after hours at $19.11 up $0.31 or 1.65 percent on the New York Stock Exchange. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

VV Shots/iStock Editorial via Getty Images The impact of winter storms and the subsequent closure of stores weighed on Gap’s ( GAP ) results for the fourth quarter , leading to softer-than-expected results and driving shares as much as 10% lower in after-hours trading. Although the company reported its second consecutive year of topline growth and eighth straight quarter of positive comparable sales, company-wide comparable store sales of 3% missed the consensus estimate of +3.43%, while net sales of $4.236B were just slightly less than the $4.24B estimate. Gap ( GAP ) earned an unadjusted profit of $0.45 per share, which was less than $0.54 per share a year ago but in-line with expectations. Gross margin of 38.1% declined by 80 basis points from a year ago, while merchandise margin for the quarter was down 90 basis points due to an estimated net tariff impact of 200 basis points. By brand, Old Navy comparable sales increased 3% (versus +3.43% estimates) and increased by 4% for Banana Republic (versus +2.67% estimates) and 7% for the Gap stores (versus +4.38%), but fell by a much greater-than-expected 10% for the company’s Athleta banner. Net sales were up 3% for Old Navy to $2.3B, up 8% for Gap to $1.1B, and increased 1% to $549M for Banana Republic. Athleta sales, however, fell 11% to $354M, leading to a modest 2.1% increase in company-wide net sales. For Q1, Gap ( GAP ) expects net sales to increase 1% to 2%, representing a range of $3.49B and $3.53B versus $3.53B estimates. Additionally, gross margin is expected to decline by 150 to 200 basis points. For FY26, net sales are expected to increase by 2% to 3%, representing a range of $15.7B to $15.86B with a $15.78B midpoint that is above $15.75B estimates. The company also expects EPS to be between $2.20 and $2.35, with a midpoint of $2.28 that is below the $2.32 estimates. More on Gap The Gap: Too Much Pessimism Creates A Buying Opportunity The Gap, Inc. (GAP) Q3 2025 Earnings Call Transcript The Gap: Earnings Gr...

UrosPoteko/iStock via Getty Images Trulieve ( TCNNF ) has announced Q4 and full-year earnings. Results were good. On top of that, doors to growth are opening wider. With an improving regulatory picture, market penetration, and customer retention, it's time to reassess TCNNF. Summary of Previous Thesis When I wrote about Trulieve last August, I maintained my Buy rating. This was because they had proved themselves to be one of the more resilient cannabis operators in a distressed industry, which was facing margin compression plus large debt maturities. Screenshot from previous thesis (Q2 2025 Form 10Q) By comparison, Trulieve had significant cash to cover their debt obligations while also generating north of $200M in free cash flow per year. Screenshot from previous (Q2 2025 Form 10Q) Their financial strength largely drew on their concentration in Florida. This is a medical-only state, and so they had largely invested in this. Crucially, they had not leveraged more than this underlying business could support, which mattered when rescheduling marijuana as a Schedule III substance became a lower priority for President Trump. (As a reminder, cannabis operators cannot deduct expenses outside the cost of goods sold while cannabis is Schedule I.) Author's previous calculation TCNNF was $5.54 at the time. Assuming that their strong financial position would allow them to gain market share while other operators were distressed, I surmised that even lower FCF assumptions and single-digit growth pointed to undervaluation by quite a strong margin and rated it a Buy. Q4 and Full-Year 2025 Results While results for the quarter and full year were positive, it's important to note what they reflect about the industry. Revenue didn't grow much, showing how Trulieve is affected by cycles. Income Statement (2025 Form 10Q) Revenue has hovered around $1B for a few years, but the table also shows improved gross margins in that time, raising them from 52% to 60%. Cash Flow Statement (2025 Fo...

Ingram Micro ( INGM ) announced a $200M secondary offering of common stock by selling shareholder Ingram Holdco (an affiliate of Platinum Equity). The selling shareholder plans to grant underwriters a 30-day option to purchase an additional ~$37.5M in shares. All net proceeds will go to the selling shareholder, and Ingram Micro will not receive any proceeds from the offering. The company plans to repurchase at least $50M of its shares from the selling shareholder at the same net price as the offering. The buyback will be funded with cash on hand and executed under the company’s existing $100M share repurchase program. More on Ingram Micro Holding Corporation Ingram Micro Holding Corporation (INGM) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript Ingram Micro Holding Corporation (INGM) Q4 2025 Earnings Call Transcript Ingram Micro outlines double-digit cloud growth and higher AI-driven revenue for 2026 as Xvantage expands From Materials to Biotech: Mid-Caps that have stayed bullish the longest on Quant ratings Seeking Alpha’s Quant Rating on Ingram Micro Holding Corporation

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Oracle Corporation of Class Action Lawsuit and Upcoming Deadlines - ORCL PR Newswire

Earnings Call Insights: MediWound Ltd. (MDWD) Q4 2025 Management View CEO Ofer Gonen indicated 2025 was a pivotal year for MediWound, highlighting two primary growth drivers: “a Phase III VALUE trial advancing as planned and an operational expanded manufacturing facility for NexoBrid, positioning us for long-term commercial growth.” He emphasized readiness to operate amid the ongoing conflict with Iran, stating the company remains focused on clinical milestones and commercial objectives. Gonen announced enrollment is ongoing in the Phase III VALUE study for EscharEx in venous leg ulcers, with a target of 216 patients across approximately 40 sites, and expects both prespecified interim assessment and enrollment completion by year-end 2026. He also revealed plans to expand EscharEx’s clinical program into diabetic foot ulcers (DFU) and pressure ulcers, with Phase II and investigator-initiated studies beginning in the second half of 2026. The company disclosed a new research collaboration agreement with B. Braun for the EscharEx DFU Phase II study, joining an existing group of advanced wound care partners including Coloplast, ConvaTec, Essity, Molnlycke, Solventum, and MiMedx. Gonen highlighted the operational launch of the expanded NexoBrid manufacturing facility, increasing production capacity sixfold. Regulatory approvals for commercial output are expected in 2026. He cited new data showing NexoBrid’s applicability in 71% of war-related injuries and its use in recent mass casualty events, reinforcing its role in trauma care. CFO Hani Luxenburg reported, “Revenue for the fourth quarter was $1.9 million, compared to $5.8 million in the fourth quarter of 2024. The decrease was primarily driven by lower development services revenue, mainly attributable to U.S. government shutdown, which delayed budget approval and the initiation of new contractual agreements.” Luxenburg added, “As of December 31, 2025, we had $53.6 million in cash, cash equivalents and deposits, compare...

Artificial intelligence (AI) stocks have been some of the market’s most volatile names over the past year, and SoundHound AI (SOUN) is no exception. The voice-AI specialist has become one of the most heavily shorted technology stocks on Wall Street, with 134.9 million shares sold short representing roughly 35.6% of its float. Such an unusually high short interest signals that a large portion of investors are betting the stock will decline. But it also creates the conditions for a potential short squeeze if sentiment suddenly shifts. Data shows that bearish positioning in SOUN has climbed steadily in recent months, reflecting skepticism about the company’s profitability and the competitive pressures in the voice-AI market. While the voice-AI specialist has posted rapid revenue growth, it remains deeply unprofitable. Competition is another factor fueling bearish sentiment. SoundHound operates in the highly competitive voice-AI market, where it faces formidable rivals including Amazon.com, (AMZN) and Alphabet (GOOG) (GOOGL) tech giants with vastly larger resources and established ecosystems. Nevertheless, if a positive catalyst such as a major partnership or accelerating adoption of its conversational AI platform forces short sellers to cover their positions, the resulting buying pressure could trigger a sharp rally. With short interest among the highest in the tech sector, SoundHound could be the next candidate for a dramatic short-squeeze move. About SoundHound Stock Headquartered in Santa Clara, California, SoundHound is a voice-and-conversational AI company that develops speech-recognition, natural-language-processing, and voice-commerce platforms for industries such as automotive, restaurants, customer service, and smart devices. Its market cap is around $3.4 billion. SoundHound’s stock has experienced sharp volatility over the past year, reflecting both strong investor enthusiasm around AI and growing skepticism about the company’s path to profitability. Year-to-...

Earnings Call Insights: NN, Inc. (NNBR) Q4 2025 Management View CEO Harold Bevis stated that 2025 marked NN's third consecutive year of improved results, citing "increased adjusted EBITDA results toward recent company highs" and significant growth in adjusted operating income. He emphasized the completion of the "majority of the heavy spending portion of our transformation plan," with four plant closures and about 800 positions right-sized. Bevis highlighted the strategic shift: "We are intentionally shifting our sales profile towards higher-value end markets and higher-value capabilities and intentionally shifting away from low-value commodity automotive part making." Bevis reported that NN has secured more than $200 million in new business since mid-2023, with a current pipeline over $800 million and "record levels of program launches" ahead in 2026. He noted the company's first business win in the data center market, producing "high-precision water tight couplings that go into water-cooled computing equipment." The CEO announced that NN will "roughly double the amount of capital spending" for growth in 2026 versus 2025, enabled by higher EBITDA and project completions. He forecast that "2026 is going to be a year where NN returns to net sales growth, and it's happening right now in the first quarter." Bevis cautioned that "volatility remains high in our markets," citing tariffs, precious metals pricing, and geopolitical unrest, but stated that overall risk factors are similar to the prior year. CFO Christopher Bohnert stated, “On an as-reported basis, net sales for the quarter were $104.7 million... Adjusted operating income for the fourth quarter was $3.3 million... Our adjusted EBITDA was $12.9 million, as Harold mentioned, for the quarter, up from $12.1 million a year ago. On a pro forma basis, adjusted EBITDA increased $1.1 million or 9.3% year-over-year.” COO Tim French explained that “over the trailing 3 years, we have secured over $200 million of new busin...

jetcityimage Simon Property Group's ( SPG ) majority-owned partnership amended, restated, and extended its $5.0B multicurrency unsecured revolving credit facility and amended its $3.5B multicurrency unsecured credit facility, the company said on Thursday. The $5.0B facility will initially mature on June 30, 2030, and can be extended for an additional year at the operating partnership's sole option. Based on the partnership's current credit ratings, the interest rate for the U.S. dollar borrowings is 15.0 basis points lower than the prior facility's at SOFR + 65.0 bps. The partnership also amended its $3.5B facility to conform the applicable margin so that it aligns with the $5.0B revolving credit facility. Simon Property ( SPG ) stock edged up 0.2% in after-hours trading. More on Simon Property Simon Property Group, Inc. (SPG) Presents at Citi's Miami Global Property CEO Conference 2026 Transcript Simon Property Group: Firing On All Cylinders, But Strong Performance Looks Priced In Already Simon Property Group Q4: Financial Results And Preferred Stock Analysis Simon Property to buy back up to $2.0B of common stock Simon Property Group outlines $13.13 per share FFO guidance and $4B development pipeline while advancing leasing and redevelopment

Lithium Africa (TSXV: LAF) on Thursday said it is increasing the size of its previously announced private placement from C$5 million to C$8.5 million following strong investor demand. The company secured a lead order of C$3.3 million from Purpose Global Resource Fund. The offering consists of 4.25 million units at C$2 per unit, each comprising one common share and one-half of a warrant exercisable at C$2.80 for three years. The agent, ATB Cormark Capital Markets, may sell an additional 750,000 units for C$1.5 million. It will receive a 7% cash commission and broker warrants equal to 7% of units sold. Proceeds will be used toward the acquisition of the Springbok Project, as well as working capital and general corporate purposes. The offering is expected to close around March 18, 2026, subject to regulatory approvals, including TSX Venture Exchange acceptance. The securities will not be offered in the U.S. and are not registered under U.S. securities law. SOURCE Lithium Africa Corp. ( LAF:CA ) LAF:CA closed -4.53% at $2.0. Source: Press Release More on Lithium Africa Corp. Lithium Africa announces C$5 million private placement of units Seeking Alpha’s Quant Rating on Lithium Africa Corp. Financial information for Lithium Africa Corp.

Climb Bio press release ( CLYM ): Q4 GAAP EPS of -$0.26. Cash Position: Cash, cash equivalents, and marketable securities were $160.7 million as of December 31, 2025, expected to fund operations into 2028. Research and Development (R&D) expenses: R&D expenses were $13.7 million for the three months ended December 31, 2025, compared to $6.0 million for the comparable period in 2024, and were $46.7 million for the full year 2025, compared to $14.3 million for the full year 2024. General and Administrative (G&A) expenses: G&A expenses were $5.6 million for the three months ended December 31, 2025, compared to $5.0 million for the comparable period in 2024, and were $21.2 million for the full year 2025, compared to $16.0 million for the full year 2024. More on Climb Bio Cheap high flyer healthcare stocks - high momentum and low valuation Seeking Alpha’s Quant Rating on Climb Bio Historical earnings data for Climb Bio Financial information for Climb Bio

(RTTNews) - Marvell Technology, Inc. (MRVL) reported earnings for its fourth quarter that Increases, from last year The company's earnings came in at $396.1 million, or $0.46 per share. This compares with $200.2 million, or $0.23 per share, last year. Excluding items, Marvell Technology, Inc. reported adjusted earnings of $685.1 million or $0.80 per share for the period. The company's revenue for the period rose 22.1% to $2.21 billion from $1.81 billion last year. Marvell Technology, Inc. earnings at a glance (GAAP) : -Earnings: $396.1 Mln. vs. $200.2 Mln. last year. -EPS: $0.46 vs. $0.23 last year. -Revenue: $2.21 Bln vs. $1.81 Bln last year. -Guidance: Next quarter EPS guidance: $ 0.79 Next quarter revenue guidance: $ 2.400 B The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Amazon Web Services announced Thursday the launch of Amazon Connect Health. This AI agent-powered platform is meant to help health care organizations automate repetitive administrative tasks including appointment scheduling, documentation, and patient verification, among other things. Amazon Connect Health is HIPAA eligible and connects with electronic health record (EHR) software. The platform is currently partnered with EHR software providers, data integrators, and patient engagement companies, the company said. This move is not the cloud giant’s first in the health care space, and it comes at a time when AWS is increasingly looking to grow its footprint in the $5 trillion U.S. health care industry. The company launched Amazon Comprehend Medical, a HIPAA-eligible natural language processor for unstructured medical data in 2018, and it launched Amazon HealthLake in 2021 which is HIPAA-eligible Fast Healthcare Interoperability Resources (FHIR) infrastructure used to organize health data. The company also launched HealthOmics, a bioinformatics workflow, in 2022. Still, it is its first major product offering AI agents — software that completes complex tasks on behalf of a human — within a regulatory compliant platform. Amazon Connect Health works with existing clinician software to manage the administrative workflow of providers, like medical history reviews, medical coding, and clinical documentation, the company said. Amazon Connect Health currently offers patient verification and ambient documentation. Appointment scheduling and patient insights are in preview, and medical coding and other features are set to roll out to customers later. The software costs $99 a month per user for up to 600 encounters a month — AWS said most primary care physicians have up to 300 encounters a month. An Amazon Web Services spokesperson did not immediately respond to TechCrunch’s requests for additional information regarding testing and timeline. Techcrunch event Disrupt 2026: The te...

The investing app is stepping into the premium credit-card market long dominated by American Express and big banks.

财联社3月6日讯（编辑 牛占林） 美东时间周四，随着围绕伊朗的冲突持续升级并对中东以外地区产生外溢影响，美股剧烈动荡，全球市场波动性上升，油价飙升至2024年年中以来最高水平。 道琼斯指数盘中跌幅一度超过1100点，随后在下午时段收复部分失地。其他两大指数也较盘中低点有所回升，最终仍小幅收跌。 油价方面，美国原油价格大涨8.5%，升至每桶81美元以上，创下自2020年5月以来最大单日涨幅。国际基准布伦特原油上涨4.93%，至每桶85.41美元。 本周以来，美国原油和布伦特原油价格分别累计上涨逾20%和17%，市场对霍尔木兹海峡石油运输受阻的担忧持续升温。 数据显示，由于冲突升级，战争似乎已经完全中断了油轮通过霍尔木兹海峡的航行。不过伊朗常驻联合国代表团当地时间5日在社交媒体发文表示，所谓伊朗封锁霍尔木兹海峡的说法毫无根据，荒谬至极，伊朗始终恪守国际法，维护航行自由。 与此同时，美国天然气期货上涨近3%，柴油期货上涨约7%。能源价格走高可能推升通胀，从而使美联储的政策前景更加复杂，也给股市带来压力。 三菱日联金融集团高级外汇经济学家Lee Hardman在报告中表示：“当前的不确定性仍然很高，市场尚无法判断冲突将持续多久，以及全球能源供应会受到多大程度的冲击。” 美国银行高级投资策略主管Rob Haworth表示，市场关注的核心问题包括：一是霍尔木兹海峡的航运是否能够恢复；二是战争将持续多久。 他指出：“市场一直希望这场冲突是短暂的。但冲突范围一直在扩大，如果战争持续时间更长、影响进一步扩散，风险资产的情绪可能会明显恶化。” 市场动态 截至收盘，道指跌784.67点，跌幅为1.61%，报47954.74点；纳指跌58.50点，跌幅为0.26%，报22748.99点；标普500指数跌38.82点，跌幅为0.57%，报6830.68点。 在板块方面，标普500指数中工业、原材料和医疗保健板块跌幅居前，其中客运航空子行业大幅下挫。 美股行业ETF中，日常消费ETF和医疗保健ETF跌约2%，油气ETF则涨1.88%，能源精选ETF涨0.53%，可选消费精选ETF涨0.11%。 热门股表现 大型科技股涨跌不一，微软涨1.35%，亚马逊涨0.98%，英伟达涨0.16%，特斯拉跌0.10%，谷歌A跌0.74%，苹果跌0.85%，Meta跌1.07%。 芯片设计公司博通发布强劲业绩展...

thamerpic/iStock Editorial via Getty Images Glencore ( GLCNF ) ( GLNCY ) has proposed to support a little-known Kazakh entrepreneur's $1.4B bid to buy a 40% stake in miner Eurasian Resources Group, the Financial Times reported Thursday. Glencore ( GLCNF ) ( GLNCY ) reportedly offered an $800M upfront pre-payment in exchange for future shipments of ferrochrome, mainly used in steel production, to help finance Shakhmurat Mutalip's bid, which is close to being finalized, having overtaken a rival bid from Shukhrat Ibragimov, the CEO of Eurasian Resources and son of the company's co-founder. Mutalip and Glencore ( GLCNF ) ( GLNCY ) also are in active discussions over his bid to acquire Glencore's 70% stake in another Kazakh miner, Kazzinc, which FT previously reported could be worth ~$3.5B. Any transaction would require the approval of all three major shareholders, which has not yet been secured, as well as the Kazakhstan government, which owns a 40% stake. More on Glencore Glencore Q4 2025 Earnings Call Presentation Of The World's Five Biggest Copper Producers, Only Glencore Is Still A Glencore And Venezuelan Oil: Who Wins? Who Loses?

Marvell’s stock was up in after-hours trading on Thursday after an upbeat earnings report and full-year guidance.

Former US Energy Secretary and CEO of the EFI Foundation Ernest Moniz discusses the potential impact of ongoing tensions in the Middle East on global energy markets. Moniz sees multiple options on the table to ease the financial burden on consumers, including releasing oil. He talks with Romaine Bostick and Katie Greifeld on "The Close." (Source: Bloomberg)

Seeking Alpha Seeking Alpha Seeking Alpha Seeking Alpha More on Costco Costco Q2 Earnings Preview: Shoppers Bleed, COST Feeds Costco: A Strong Business Model For Long-Term Investors Costco's 2x P/E Over Amazon Is Not Irrational (Rating Upgrade) Costco sees stronger sales growth than retail peers in FQ2 Costco Q2 earnings preview: Strong comps, membership income in focus